Overview A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer Status: Not yet recruiting Trial end date: 2026-06-01 Target enrollment: Participant gender: Summary This is a first-in-human phase I/II study to examine the safety, tolerability and preliminary efficacy of VLS-1488 in subjects with advanced cancers. Phase: Phase 1/Phase 2 Details Lead Sponsor: Volastra Therapeutics, Inc.